Tearsheet

American Well (AMWL)


Market Price (12/4/2025): $4.4 | Market Cap: $71.3 Mil
Sector: Health Care | Industry: Health Care Technology

American Well (AMWL)


Market Price (12/4/2025): $4.4
Market Cap: $71.3 Mil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -196%
Weak multi-year price returns
2Y Excs Rtn is -135%, 3Y Excs Rtn is -167%
Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -123 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -46%
1 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics.
  Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6%, Rev Chg QQuarterly Revenue Change % is -7.8%
2   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -24%
3   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -118%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -196%
1 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics.
2 Weak multi-year price returns
2Y Excs Rtn is -135%, 3Y Excs Rtn is -167%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -123 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -46%
4 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6%, Rev Chg QQuarterly Revenue Change % is -7.8%
5 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -24%
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -118%

Valuation, Metrics & Events

AMWL Stock


Why The Stock Moved


Qualitative Assessment

AI Generated Analysis | Feedback



1. Significant year-over-year decline in total revenue and visit volume: In its Q3 2025 earnings report, released on November 4, 2025, American Well announced an 8% year-over-year decrease in total revenue to $56.3 million, alongside a 21% drop in total visit volume. This signals a contraction in core business activity and a potential concern for future growth.

2. Continued net losses: American Well reported a net loss of $31.9 million for the third quarter of 2025. This followed a net loss of $19.5 million in the second quarter of 2025. Persistent unprofitability can negatively impact investor confidence and valuation.

Show more

Stock Movement Drivers

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
AMWL Return--76%-53%-47%-76%-44%-99%
Peers Return19%16%-4%-24%2%-26%-24%
S&P 500 Return16%27%-19%24%23%16%112%

Monthly Win Rates [3]
AMWL Win Rate33%17%33%42%42%20% 
Peers Win Rate20%23%23%27%27%49% 
S&P 500 Win Rate58%75%42%67%75%70% 

Max Drawdowns [4]
AMWL Max Drawdown--77%-57%-67%-83%-48% 
Peers Max Drawdown-16%-2%-32%-33%-23%-36% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: OMCL, MDRX, BEAT, CARL, HTFL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)

How Low Can It Go

Unique KeyEventAMWLS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-97.8%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven4435.3%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-44.1%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven78.9%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven71 days148 days

Compare to OMCL, MDRX, BEAT, CARL, HTFL


In The Past

American Well's stock fell -97.8% during the 2022 Inflation Shock from a high on 1/27/2021. A -97.8% loss requires a 4435.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About American Well (AMWL)

Better Bets than American Well (AMWL)

Trade Ideas

Select past ideas related to AMWL. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
4.1%4.1%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-9.8%-9.8%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
6.0%6.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
9.7%9.7%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
6.2%6.2%-5.1%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
4.1%4.1%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-9.8%-9.8%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
6.0%6.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
9.7%9.7%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
6.2%6.2%-5.1%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for American Well

Peers to compare with:

Financials

AMWLOMCLMDRXBEATCARLHTFLMedian
NameAmerican.Omnicell Veradigm HeartBeamCarlsmed HeartFlow 
Mkt Price4.0840.485.000.7016.9928.0010.99
Mkt Cap0.11.80.50.0--0.3
Rev LTM2651,178588033139202
Op Inc LTM-12317-20-21-24-61-22
FCF LTM-649483-15-30-90-23
FCF 3Y Avg-134126-79-13---46
CFO LTM-62153116-15-29-85-22
CFO 3Y Avg-120183-22-13---17

Growth & Margins

AMWLOMCLMDRXBEATCARLHTFLMedian
NameAmerican.Omnicell Veradigm HeartBeamCarlsmed HeartFlow 
Rev Chg LTM4.3%10.7%1.8%---4.3%
Rev Chg 3Y Avg-0.6%-3.0%-20.1%----3.0%
Rev Chg Q-7.8%10.0%-9.7%----7.8%
QoQ Delta Rev Chg LTM-1.8%2.5%-2.5%----1.8%
Op Mgn LTM-46.4%1.5%-3.3%--71.4%-44.4%-44.4%
Op Mgn 3Y Avg-78.7%-2.0%4.4%----2.0%
QoQ Delta Op Mgn LTM5.9%0.1%-13.3%---0.1%
CFO/Rev LTM-23.4%13.0%19.7%--86.4%-61.5%-23.4%
CFO/Rev 3Y Avg-46.0%16.0%-4.1%----4.1%
FCF/Rev LTM-24.3%8.0%14.2%--88.9%-65.0%-24.3%
FCF/Rev 3Y Avg-51.2%11.0%-14.2%----14.2%

Valuation

AMWLOMCLMDRXBEATCARLHTFLMedian
NameAmerican.Omnicell Veradigm HeartBeamCarlsmed HeartFlow 
Mkt Cap0.11.80.50.0--0.3
P/S0.41.20.9---0.9
P/EBIT-0.880.9-8.8-2.1---1.4
P/E-0.969.6-5.9-2.1---1.5
P/CFO-1.69.04.4-2.7--1.4
Total Yield-113.7%1.4%-17.0%-48.1%---32.6%
Dividend Yield0.0%0.0%0.0%0.0%--0.0%
FCF Yield 3Y Avg-77.6%6.9%-1.5%-27.2%---14.3%
D/E0.10.10.40.0--0.1
Net D/E-2.00.0-0.4-0.1---0.3

Returns

AMWLOMCLMDRXBEATCARLHTFLMedian
NameAmerican.Omnicell Veradigm HeartBeamCarlsmed HeartFlow 
1M Rtn-19.8%21.3%4.2%-59.8%39.0%-17.8%-6.8%
3M Rtn-41.4%23.3%1.0%-49.7%31.1%-10.5%-4.7%
6M Rtn-41.0%29.4%16.3%-58.1%---12.4%
12M Rtn-55.1%-13.7%-52.6%-76.1%---53.9%
3Y Rtn-94.7%-20.4%-73.8%-84.9%---79.3%
1M Excs Rtn-19.8%21.3%4.2%-59.7%39.1%-17.7%-6.8%
3M Excs Rtn-44.6%16.9%-4.3%-55.0%26.3%-23.2%-13.8%
6M Excs Rtn-55.8%14.7%1.6%-72.8%---27.1%
12M Excs Rtn-70.9%-26.7%-65.5%-90.5%---68.2%
3Y Excs Rtn-166.8%-89.6%-145.3%-158.8%---152.0%

Financials

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Single Segment259    
Other 32283024
Platform subscription 1211089884
Visits 12411711741
Total259277253245149


Price Behavior

Short Interest

Short Interest: As Of Date11142025
Short Interest: Shares Quantity156,577
Short Interest: % Change Since 1031202510.2%
Average Daily Volume149,491
Days-to-Cover Short Interest1.05
Basic Shares Quantity16,214,711
Short % of Basic Shares1.0%

SEC Filings

Expand for More

Report DateFiling DateFiling
93020251104202510-Q 9/30/2025
6302025805202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024212202510-K 12/31/2024
93020241030202410-Q 9/30/2024
6302024731202410-Q 6/30/2024
3312024501202410-Q 3/31/2024
12312023215202410-K 12/31/2023
93020231101202310-Q 9/30/2023
6302023802202310-Q 6/30/2023
3312023503202310-Q 3/31/2023
12312022223202310-K 12/31/2022
93020221108202210-Q 9/30/2022
6302022805202210-Q 6/30/2022
3312022510202210-Q 3/31/2022
12312021228202210-K 12/31/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value
Value of
Held Shares
Form
0Zamansky DmitryChief Product & Tech. Officer9042025Sell6.7725,605173,4071,338,978Form
1Jackson Deborah C 9042025Sell6.794,53130,759296,411Form
2Gotlib PhyllisPresident, International9042025Sell6.784,78132,422895,904Form
3McNeice Paul FrancisChief Accounting Officer9042025Sell6.7811376626,394Form
4Jackson Deborah C 8212025Sell7.104,53132,182342,308Form